GCH1 and neoplasm: Ki67 immunohistochemical staining showed a decreased percentage of proliferating (Ki67+) tumor cells after the administration of niraparib and DAHP (Figure 7(d)), suggesting that the combination of GCH1 inhibitors and niraparib potently reined back tumor growth.